24 Country: USA Intervention setting: University-based mental health clinic Enrollment period: NR Funding: National Institutes of Health (NIH) Centers for Disease Control (CDC) Agency for Healthcare Research and Quality National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD) International Obsessive- Compulsive Disorder Foundation (IOCDF) Intervention: Cognitive-behavioral therapy (CBT),16 weekly sessions with 3 month follow-up Assessments: Clinician-rated measurements PARS ADIS-C/P Clinical Global Impression (CGI)-Severity and Improvement Parent-rated measures Child Behavior Checklist (CBCL) Columbia Impairment Scale-Parent Version (CIS-P) Multidimensional Anxiety Scale for Children-Parent Version (MASC-P) Social Responsiveness Scale (SRS) SACA Child-Rated Measures Revised Children’s Manifest Anxiety Scale (RCMAS) Groups: G1: CBT G2: standard care Inclusion criteria: • diagnosis of autism, Asperger’s syndrome, or PDD- NOS diagnosed by ADI-R and ADOS • primary diagnosis of separation anxiety disorder (SAD), social phobia, generalized anxiety disorder (GAD), or obsessive compulsive disorder (OCD) • age 7-11 years old Exclusion criteria: • full scale or verbal comprehension IQ ˂ 70 on a standardized test • concurrent participation in psychosocial interventions • suicidality or suicidal behavior in the last six months • diagnosis of BPAD or psychotic disorder Age, mean/yrs ± SD: G1: 8.83 ± 1.31 G2: 8.95 ± 1.40 Overall ratings: Global Rating of Severity, mean ± SD: CGI-Severity : G1: 3.50 ± 0.72 G2: 4.00 ± 0.63 Social skills: SRS total, mean ± SD: G1: 100.83 ± 25.10 G2: 110.14 ± 22.41 SRS, awareness, mean ± SD: G1: 12.67 ± 3.94 G2: 12.67 ± 3.14 SRS, motivation, mean ± SD: G1: 14.33 ± 4.86 G2: 19.10 ± 5.37 SRS, mannerisms, mean ± SD: G1: 19.63 ± 5.86 G2: 20.62 ± 6.75 Communication/ language: SRS, communication, mean ± SD: G1: 33.83 ± 9.31 G2: 36.67 ± 7.83 Problem behavior: CIS-P, mean ± SD: G1: 21.13 ± 9.51 Overall ratings: Global Rating of Severity, mean ± SD: CGI-Severity : G1: 2.67 ± 0.48 G2: 3.57 ± 0.87 p ˂ 0.01 3-month follow-up G1: 2.73 ± 0.96 p ˂ 0.01 vs. baseline Social skills: SRS total, mean ± SD: G1: 88.88 ± 19.85 G2: 106.19 ± 26.00 p ˂ 0.05 3-month follow-up G1: 93.33 ± 27.64 p=NS SRS, awareness, mean ± SD: G1: 12.04 ± 2.63 G2: 12.57 ± 3.67 p=NS 3-month follow-up G1: 12.00 ± 3.32 p ˂ 0.05 vs. baseline SRS, motivation, mean ± SD: G1: 12.46 ± 3.91 G2: 17.57 ± 5.64 p=NS 3-month follow-up G1: 14.00 ± 6.65 p=NS vs. baseline C-50 T ourette Syndrome Association Janssen Pharmaceuticals Design: RCT Provider: Therapists Parents Self-therapy Treatment manual followed: Yes Defined protocol followed: Yes Measure of treatment fidelity reported: Yes Co-interventions held stable during treatment: NR Concomitant therapies, n (%): SSRI: G1: 6 (25) G2: 4 (19) Atypical antipsychotic: G1: 2 (8.3) G2: 5 (23.8) Stimulant, atomoxetine, or guanfacine: G1: 7 (29.2) G2: 7 (33.3) Benzodiazepine: G1: 0 G2: 1 (4.8) N at enrollment: G1: 24 G2: 21 Mental age, mean/yrs (range): NR Sex: M, n (%): G1 : 19 (79.2) G2 : 17 (81) F, n (%): G1 : 5 (20.8) G2 : 4 (19)